↓ Skip to main content

Cochrane Database of Systematic Reviews

Gene therapy for sickle cell disease

Overview of attention for article published in Cochrane database of systematic reviews, November 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
wikipedia
1 Wikipedia page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
33 Mendeley
Title
Gene therapy for sickle cell disease
Published in
Cochrane database of systematic reviews, November 2016
DOI 10.1002/14651858.cd007652.pub5
Pubmed ID
Authors

Abiola Olowoyeye, Charles I Okwundu

Abstract

Sickle cell disease encompasses a group of genetic disorders characterized by the presence of at least one hemoglobin S (Hb S) allele, and a second abnormal allele that could allow abnormal hemoglobin polymerisation leading to a symptomatic disorder.Autosomal recessive disorders (such as sickle cell disease) are good candidates for gene therapy because a normal phenotype can be restored in diseased cells with only a single normal copy of the mutant gene. This is an update of a previously published Cochrane Review. The objectives of this review are:to determine whether gene therapy can improve survival and prevent symptoms and complications associated with sickle cell disease;to examine the risks of gene therapy against the potential long-term gain for people with sickle cell disease. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which comprises of references identified from comprehensive electronic database searches and searching relevant journals and abstract books of conference proceedings.Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 15 August 2016. All randomised or quasi-randomised clinical trials (including any relevant phase 1, 2 or 3 trials) of gene therapy for all individuals with sickle cell disease, regardless of age or setting. No trials of gene therapy for sickle cell disease were found. No trials of gene therapy for sickle cell disease were reported. No randomised or quasi-randomised clinical trials of gene therapy for sickle cell disease were reported. Thus, no objective conclusions or recommendations in practice can be made on gene therapy for sickle cell disease. This systematic review has identified the need for well-designed, randomised controlled trials to assess the benefits and risks of gene therapy for sickle cell disease.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 21%
Student > Ph. D. Student 5 15%
Student > Bachelor 4 12%
Other 2 6%
Lecturer 2 6%
Other 4 12%
Unknown 9 27%
Readers by discipline Count As %
Medicine and Dentistry 12 36%
Biochemistry, Genetics and Molecular Biology 6 18%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Psychology 2 6%
Nursing and Health Professions 1 3%
Other 1 3%
Unknown 9 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 April 2018.
All research outputs
#6,376,470
of 21,094,310 outputs
Outputs from Cochrane database of systematic reviews
#8,296
of 12,077 outputs
Outputs of similar age
#135,964
of 420,898 outputs
Outputs of similar age from Cochrane database of systematic reviews
#109
of 156 outputs
Altmetric has tracked 21,094,310 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 12,077 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.7. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,898 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 156 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.